Why the study?
To evaluate the impact of implementing a high sensitivity cardiac troponin I assay on long term outcomes in patients with suspected acute coronary syndrome.
Does the implementation of a high sensitivity cardiac troponin I assay reduce myocardial infarction or death in patients with suspected acute coronary syndrome?
Does the implementation of a high sensitivity cardiac troponin I assay reduce myocardial infarction or death in patients with suspected acute coronary syndrome?
Implementing a high-sensitivity cardiac troponin I assay with sex-specific thresholds is associated with improved long-term outcomes, particularly by identifying risk in patients with non-ischemic myocardial injury.
Answers are grounded in this paper and cite their sources.
May support high-sensitivity troponin use in suspected ACS; leaves open need for RCTs to confirm outcome benefit.
OBJECTIVE: To evaluate the impact of implementing a high sensitivity assay for cardiac troponin I on long term outcomes in patients with suspected acute coronary syndrome. DESIGN: Secondary observational analysis of a stepped wedge, cluster randomised controlled trial. SETTING: 10 secondary and tertiary care centres in Scotland, UK. PARTICIPANTS: 48 282 consecutive patients with suspected acute coronary syndrome. Myocardial injury was defined as any high sensitivity assay result for cardiac troponin I >99th centile of 16 ng/L in women and 34 ng/L in men. INTERVENTION: Hospital sites were randomly allocated to either early (n=5 hospitals) or late (n=5 hospitals) implementation of a high sensitivity cardiac troponin I assay with sex specific diagnostic thresholds. MAIN OUTCOME MEASURE: The main outcome was myocardial infarction or death at five years. RESULTS: 53.9% (567/1051), respectively, in those reclassified by the high sensitivity assay (0.82, 0.72 to 0.94). After implementation of the high sensitivity assay, a reduction in subsequent myocardial infarction or death was observed in patients with non-ischaemic myocardial injury (0.83, 0.75 to 0.91) but not in those with type 1 or type 2 myocardial infarction (0.92, 0.83 to 1.01 and 0.98, 0.84 to 1.14). CONCLUSIONS: Implementation of a high sensitivity cardiac troponin I assay in the assessment of patients with suspected acute coronary syndrome was associated with a reduced risk of subsequent myocardial infarction or death at five years in those reclassified by the high sensitivity assay. Improvements in outcome were greatest in patients with non-ischaemic myocardial injury, suggesting a broader benefit beyond the identification of myocardial infarction. TRIAL REGISTRATION: ClinicalTrials.gov NCT01852123.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: